Literature DB >> 8648709

Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

V M Hirsch1, T R Fuerst, G Sutter, M W Carroll, L C Yang, S Goldstein, M Piatak, W R Elkins, W G Alvord, D C Montefiori, B Moss, J D Lifson.   

Abstract

The dynamics of plasma viremia were explored in a group of 12 simian immunodeficiency virus (SIV)-infected rhesus macaques (Macaca mulatta) that had received prior immunization with either nonrecombinant or trivalent (gag-pol, env) SIV-recombinant vaccinia viruses. Three distinct patterns of viral replication observed during and following primary viremia accounted for significant differences in survival times. High-level primary plasma viremia with subsequently increasing viremia was associated with rapid progression to AIDS (n = 2). A high-level primary plasma virus load with a transient decline and subsequent progressive increase in viremia in the post-acute phase of infection was associated with progression to AIDS within a year (n = 6). Low levels of primary plasma viremia followed by sustained restriction of virus replication were associated with maintenance of normal lymphocyte subsets and intact lymphoid architecture (n = 4), reminiscent of the profile observed in human immunodeficiency virus type 1-infected long-term nonprogressors. Three of four macaques that showed this pattern had been immunized with an SIV recombinant derived from the attenuated vaccinia virus, modified vaccinia virus Ankara. These data link the dynamics and extent of virus replication to disease course and suggest that sustained suppression of virus promotes long-term, asymptomatic survival of SIV-infected macaques. These findings also suggest that vaccine modulation of host immunity may have profound beneficial effects on the subsequent disease course, even if sterilizing immunity is not achieved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648709      PMCID: PMC190250     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy.

Authors:  P Biberfeld; K J Chayt; L M Marselle; G Biberfeld; R C Gallo; M E Harper
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

2.  In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals.

Authors:  M A Cochran; C Puckett; B Moss
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

3.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

4.  A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment.

Authors:  J A Koziol; D A Maxwell; M Fukushima; M E Colmerauer; Y H Pilch
Journal:  Biometrics       Date:  1981-06       Impact factor: 2.571

5.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

7.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.

Authors:  L D Giavedoni; V Planelles; N L Haigwood; S Ahmad; J D Kluge; M L Marthas; M B Gardner; P A Luciw; T D Yilma
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys.

Authors:  G B Baskin; L N Martin; M Murphey-Corb; F S Hu; D Kuebler; B Davison
Journal:  AIDS Res Hum Retroviruses       Date:  1995-02       Impact factor: 2.205

View more
  131 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

5.  Wide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus.

Authors:  S Goldstein; I Ourmanov; C R Brown; B E Beer; W R Elkins; R Plishka; A Buckler-White; V M Hirsch
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.

Authors:  Claire Ham; Priya Srinivasan; Rigmor Thorstensson; Ernst Verschoor; Zahra Fagrouche; Leonardo Sernicola; Artur Ramos; Fausto Titti; Neil Almond; Neil Berry
Journal:  J Clin Microbiol       Date:  2010-04-28       Impact factor: 5.948

7.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx.

Authors:  Richard Onanga; Christopher Kornfeld; Ivona Pandrea; Jerome Estaquier; Sandrine Souquière; Pierre Rouquet; Virginie Poaty Mavoungou; Olivier Bourry; Souleymane M'Boup; Françoise Barré-Sinoussi; François Simon; Cristian Apetrei; Pierre Roques; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics.

Authors:  R A Parker; M M Regan; K A Reimann
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.